First-in-human study of ABBV-637, an EGFR-targeting BCL-XL-inhibiting antibody-drug conjugate combined with osimertinib (OSI) in relapsed/refractory, EGFR-mutated non-small cell lung cancer (NSCLC)

被引：3
|
作者：
Rotow, J. K. [1 ]
Waqar, S. N. [2 ]
Papadopoulos, K. P. [3 ]
Hung, J-Y. [4 ,5 ]
Spira, A. I. [6 ]
Gan, H. [7 ]
Yoshida, T. [8 ]
Kuo, C-H. S. [9 ]
Doger de Speville, B. [10 ]
Felip, E. [11 ]
Yoh, K. [12 ]
Morrison-Thiele, G. [13 ]
Robinson, R. [14 ]
Rudraganguly, N. [14 ]
Saab, R. [15 ]
Cho, B. C. [16 ]
机构：
[1] Dana Farber Canc Inst, Dept Med Oncol, Lowe Ctr Thorac Oncol, Boston, MA USA
[2] Washington Univ, Med, Sch Med St Louis, Siteman Canc Ctr, St Louis, MO USA
[3] South Texas Accelerated Res Therapeut START, Dept Clin Res, San Antonio, TX USA
[4] Kaohsiung Med Univ, Div Pulm & Crit Care Med, Dept Internal Med, Kaohsiung, Taiwan
[5] Kaohsiung Med Univ, Kaohsiung Municipal Ta Tung Hosp, Coll Med, Fac Med, Kaohsiung, Taiwan
[6] Virginia Canc Specialists, Dept Med Oncol, US Oncol Res, Fairfax, VA USA
[7] Austin Hlth Austin Hosp, Dept Med Oncol, Heidelberg, Vic, Australia
[8] Natl Canc Ctr, Dept Expt Therapeut, Tokyo, Japan
[9] Chang Gung Univ, Chang Gung Mem Hosp, Div Thorac Oncol & Intervent Bronchoscopy, Dept Resp Med, Taipei, Taiwan
[10] START Madrid Hosp Univ, Fdn Jimenez Diaz, Madrid, Spain
[11] Vall dHebron Univ Hosp, Med Oncol Serv, Lung Canc Unit, Barcelona, Spain
[12] Natl Canc Ctr Hosp East, Dept Thorac Oncol, Kashiwa, Chiba, Japan
[13] AbbVie Inc, Oncol Early Discovery, Headquarters, N Chicago, IL USA
[14] AbbVie Inc, San Francisco, CA USA
[15] AbbVie Inc, Clin Res, San Francisco, CA USA
[16] Yonsei Univ, Med Oncol Dept 501, ABMRC, Seoul, South Korea
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.2352
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1318MO
引用
收藏
页数：1
相关论文
共 48 条
  • [21] Amivantamab plus lazertinib vs osimertinib as first-line treatment among Asian patients with EGFR-mutated, advanced non-small cell lung cancer (NSCLC): MARIPOSA subgroup analysis
    Lu, S.
    Cho, B. C.
    Lee, J-S.
    Lee, S-H.
    Danchaivijitr, P.
    Liu, B.
    Alip, A.
    Xiong, H.
    How, S. H.
    Chang, G-C.
    Yang, J. C-H.
    Yoshioka, H.
    Xia, K.
    Martinez, M.
    Bauml, J. M.
    Sethi, S.
    Hayashi, H.
    ANNALS OF ONCOLOGY, 2023, 34 : S1661 - S1661
  • [22] Phase 1/1b study of telisotuzumab vedotin (Teliso-V) plus osimertinib (Osi), after failure on prior Osi, in patients with advanced, c-Met overexpressing, EGFR-mutated non-small cell lung cancer (NSCLC).
    Goldman, Jonathan W.
    Horinouchi, Hidehito
    Cho, Byoung Chul
    Tomasini, Pascale
    Dunbar, Martin
    Hoffman, David
    Parikh, Apurvasena
    Blot, Vincent
    Camidge, D. Ross
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [23] ABBV-400, a c-Met protein-targeting antibody-drug conjugate (ADC), in patients (Pts) with advanced EGFR wildtype (WT) non-squamous (NSQ) non-small cell lung cancer (NSCLC): Results from a phase I study
    De Miguel, M.
    Yamamoto, N.
    Raimbourg, J.
    Cho, B. C.
    Gottfried, M.
    Stemmer, S. M.
    Goldman, J. W.
    Blaney, M. E.
    Jennaro, T.
    Vasilopoulos, A.
    Li, R. R.
    Freise, K. J.
    Aristide, M. R. Neagu
    Morrison-Thiele, G.
    Hunter, Z. N.
    Burns, M.
    Camidge, D. R.
    ANNALS OF ONCOLOGY, 2024, 35 : S805 - S806
  • [24] Real-World Study of EGFR-TKI Rechallenge With Another TKI After First-Line Osimertinib Discontinuation in Patients With EGFR-Mutated Non-Small Cell Lung Cancer: A Subset Analysis of the Reiwa Study
    Sonehara, Kei
    Tateishi, Kazunari
    Yoh, Kiyotaka
    Usui, Kazuhiro
    Hosomi, Yukio
    Kishi, Kazuma
    Naka, Go
    Watanabe, Kageaki
    Tamano, Shu
    Uemura, Kohei
    Kunitoh, Hideo
    THORACIC CANCER, 2025, 16 (02)
  • [25] AZD9592: An EGFR-cMET bispecific antibody-drug conjugate (ADC) targeting key oncogenic drivers in non-small-cell lung cancer (NSCLC) and beyond
    Comer, Frank
    Mazor, Yariv
    Hurt, Elaine
    Yang, Chunning
    Fleming, Ryan
    Shandilya, Harini
    Vijayakrishnan, Balakumar
    Sterba, Meghan
    Chen, Ruoyan
    Rosfjord, Edward
    Floch, Nicolas
    Rosenbaum, Anton I.
    Huang, Yue
    Yuan, Jiaqi
    Beaumont, Kevin
    Godfrey, Lisa
    McGrath, Lara
    Arnaldez, Fernanda
    Sapra, Puja
    CANCER RESEARCH, 2023, 83 (07)
  • [26] A First-in-Human Phase 1 Trial of the EGFR-cMET Bispecific Antibody JNJ-61186372 in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
    Park, K.
    Ahn, M.
    Lee, S.
    Kim, H. R.
    Hong, M. H.
    Millington, D.
    Curtis, M.
    Triantos, S.
    Chaplan, S.
    Haddish-Berhane, N.
    Knoblauch, R.
    Aguilar, Z.
    Laquerre, S.
    Lorenzi, M.
    Cho, B. C.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S344 - S345
  • [27] An AXL-specific antibody-drug conjugate shows preclinical anti-tumor activity in non-small cell lung cancer, including EGFR-inhibitor resistant NSCLC
    Koopman, Louise A.
    Janmaat, Maarten L.
    Jacobsen, Kirstine
    Terp, Mikkel Green
    Gresnigt-van den Heuvel, Elke
    Forssman, Ulf
    Lingnau, Andreas
    Parren, Paul W.
    Ditzel, Henrik
    Breij, Esther C.
    CANCER RESEARCH, 2018, 78 (13)
  • [28] The study of primary and acquired resistance to first-line osimertinib to improve the outcome of EGFR-mutated advanced Non-small cell lung cancer patients: the challenge is open for new therapeutic strategies
    Ferro, Alessandra
    Marinato, Gian Marco
    Mulargiu, Cristiana
    Marino, Monica
    Pasello, Giulia
    Guarneri, Valentina
    Bonanno, Laura
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2024, 196
  • [29] Phase I study of ABBV-399, a c-Met antibody-drug conjugate (ADC), as monotherapy and in combination with erlotinib in patients (pts) with non-small cell lung cancer (NSCLC).
    Angevin, Eric
    Strickler, John H.
    Weekes, Colin D.
    Heist, Rebecca Suk
    Morgensztern, Daniel
    Nemunaitis, John J.
    Fan, Xiaolin
    Beaulieu, Juliette
    Motwani, Monica
    Afar, Daniel E.
    Naumovski, Louie
    Kelly, Karen
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [30] First-in-human phase I study of BEBT-109 in previously treated EGFR exon 20 insertion-mutated advanced non-small cell lung cancer
    Zeng, Liang
    Song, Lianxi
    Liu, Li
    Wu, Fang
    Xu, Qinqin
    Yan, Huan
    Lin, Shaoding
    Jiang, Wenjuan
    Wang, Zhan
    Deng, Li
    Qin, Haoyue
    Zhang, Xing
    Xiao, Jiwen
    Liu, Min
    Liu, Zhaoyi
    Zhang, Lin
    Zhou, Chunhua
    Xiong, Yi
    Wang, Ya
    Zhang, Yongchang
    Yang, Nong
    MED, 2024, 5 (05): : 445 - 458
12345